UroGen Pharma URGN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $140.49M+28.0% | $109.79M+13.8% | $96.52M+2.4% | $94.24M+2.6% | $91.87M+1.6% | ||
| -$133.23M+13.2% | -$153.49M+6.8% | -$164.64M-6.2% | -$154.97M-11.9% | -$138.43M-9.1% | ||
| -94.8%+45.0pp | -139.8%+30.8pp | -170.6%-6.1pp | -164.4%-13.8pp | -150.7%-10.3pp | ||
| $140.49M+28.0% | $109.79M+13.8% | $96.52M+2.4% | $94.24M+2.6% | $91.87M+1.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is UroGen Pharma's revenue?
- UroGen Pharma (URGN) generated $140.5M in revenue over the trailing twelve months, up 52.9% year over year.
- Is UroGen Pharma profitable?
- UroGen Pharma is not currently profitable: it reported a net loss of $133.2M over the trailing twelve months, a -94.8% net margin.
- What are UroGen Pharma's profit margins?
- Gross margin is 89.7% and operating margin is -329.7%, with a -94.8% net margin.
- Where does UroGen Pharma's income statement data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
